Secondary Breast Cancer Sociodemographic Characteristics and Survival by Age Group

Candice A. M. Sauder, MD1,2, Qian Li, MS3, Richard J. Bold, MD1,2, Kathryn J. Ruddy, MD4, and Theresa H. M. Keegan, PhD3,5

1Division of Surgical Oncology, Department of Surgery, Davis Medical Center, University of California, Sacramento, CA; 2Comprehensive Cancer Center, Davis Medical Center, University of California, Sacramento, CA; 3Division of Hematology and Oncology, Center for Oncology Hematology Outcomes Research and Training (COHORT), University of California Davis School of Medicine, Sacramento, CA; 4Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN; 5Division of Hematology and Oncology, Department of Internal Medicine, Davis Medical Center, University of California, Sacramento, CA

ABSTRACT

Background. Secondary cancers account for 16% of all new cancer diagnoses, with breast cancer (BC) the most common secondary cancer. We have shown that secondary BC has unique characteristics and decreased survival compared with primary BC in adolescent and young adults (AYA; 15–39 years old). However, older BC populations are less well studied.

Methods. Females (age ≥15 years) diagnosed with primary BC during 1991–2015 (n = 377,167) and enrolled in the California Cancer Registry were compared with those with secondary BC (n = 37,625) by age (15–39, 40–64, ≥65 years). We examined BC-specific survival (BCSS) accounting for other causes of death as a competing risk using multivariable Cox proportional hazards regression.

Results. Most secondary BC patients were of older age (15–39, n = 777; 40–64, n = 15,848; ≥65, n = 21,000). Compared with primary BC treatment, secondary BCs were more often treated with mastectomy and less often with chemotherapy and/or radiation. BCSS was shorter in secondary BC patients than primary BC patients, but the survival difference between secondary and primary BC diminished with age [15–39 hazard ratio (HR): 2.09, 95% confidence interval (CI) 1.83–2.39; 40–64 HR: 1.51; 95% CI 1.44–1.58; ≥65 HR: 1.14; 95% CI 1.10–1.19]. Survival differences were most pronounced in women with hormone receptor positive disease and Hispanic and Asian/Pacific Islanders 40–64 years of age.

Conclusions. When BC is diagnosed following a prior cancer of any organ site, BCSS is worse than when compared with patients for whom BC is the primary diagnosis, suggesting that we may need to tailor our treatments for women with secondary BC.

There are nearly 16.9 million cancer survivors living in the United States, and the number continues to rise with ongoing improvements in treatment and screening. In this extended lifetime of survivorship, many survivors of both childhood and adult-onset malignancies go on to develop a secondary malignancy, as more than 16% of new cancer diagnoses in the United States are second cancers. Breast cancer (BC) is the most common secondary malignancy in women over the age of 15, occurring after many types of primary malignancies, including a first primary BC. Multiple studies have shown that the adolescent and young adult (AYA) female population (15–39 years of age) has the highest absolute excess risk for secondary malignancies of any age group.
For AYAs, primary and secondary BCs have distinct characteristics, with secondary BCs more often presenting with some good prognostic characteristics, including earlier stage, at low histologic grade, and with lymph node negativity. Despite this, being diagnosed with a secondary BC has been found to be an independent risk factor for worse overall survival in multivariable analysis. AYA survivors with a secondary BC had a 20% decreased relative survival at 5 years and an overall 1.58-fold increased risk of death compared with similar aged women with a primary BC. Survival and characteristics of secondary BCs in middle-aged (40–64 years old) and older women (65 years and older) are understudied to date, despite two thirds of all cancer survivors being 65 years or older.

Therefore, we sought to better understand the clinical characteristics and survival of secondary breast malignancies by age. Using data from the large population-based California Cancer Registry (CCR), we examined demographics, clinical characteristics, and breast cancer-specific survival (BCSS) in AYA, middle-aged, and older women with secondary BC compared with primary BC. Findings from this study will help us to better understand how secondary cancers uniquely affect each of these age groups, potentially allowing tailored treatments for each population.

METHODS

Patients

We obtained data from the CCR, which is one of the largest cancer registries in the world, participates in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, and is estimated to include more than 99% of all invasive cancers diagnosed in California. We included in our analysis female California residents diagnosed with an invasive first and only BC or invasive BC as a second primary cancer after an invasive first primary cancer (soft tissue or hematologic malignancy) of any type (hereafter referred to as secondary BC) aged ≥ 15 during the period January 1, 1991, through December 31, 2015 [International Classification of Disease for Oncology, 3rd Edition, (ICD-O-3) site codes C50.0–50.9 (excluding codes for sarcoma, melanoma, neuroendocrine tumors, sweat gland tumors, and lymphoma for both primary and secondary BCs)]. Secondary BCs diagnosed within 2 months of the first primary cancer were excluded to remove what were likely multiple primary tumors. In addition, for women with two BCs, the secondary BC had to have a different histology from the first primary, occur in the contralateral breast, or occur > 5 years from the first primary.

From the CCR database, we obtained information routinely recorded in the medical record at diagnosis for each primary and secondary BC patient on age at diagnosis, race/ethnicity (non-Hispanic White, Hispanic, non-Hispanic Black, and Asian or Pacific Islander, other/unknown), American Joint Committee on Cancer (AJCC) stage, tumor grade, histology, tumor size, lymph node involvement, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) tumor receptor expression status and sequence of primary cancer. The CCR has collected information on ER and PR since 1990 and on HER-2 since 1999. Because of HER-2 data incompleteness, we limited our analyses of HER-2 data to women diagnosed after 2003. ER/PR was defined as positive if either ER or PR was reported as positive, and triple-negative was defined as ER, PR, and HER-2 negative.

We also obtained registry information for each primary and secondary BC patient on initial course of treatment (surgery, chemotherapy, and radiation therapy), Census Block Group of residence at diagnosis, and vital status (routinely determined by the CCR through hospital follow-up and database linkages, including the Social Security Administration) as of December 31, 2015, and, for the deceased, the underlying cause of death. As information on patient education or other individual-level measures of socioeconomic status (SES) are not collected by the CCR, we assigned a previously developed measure of neighborhood SES based on patient address at time of diagnosis that incorporates Census Block Group on education, occupation, unemployment, household income, and poverty.

Of the 414,792 females diagnosed with a first and only, or secondary, invasive BC, we excluded patients with the histology codes noted above and unknown date of diagnosis or date of last follow-up. The resulting study population of females included 377,167 women with a first and only BC and 37,625 women with a secondary BC (Fig. 1). This study was approved by the University of California, Davis Institutional Review Board and by the California Committee for the Protection of Human Subjects.

Statistical Analysis

Multivariable logistic regression was used to compare demographic (race/ethnicity, neighborhood socioeconomic status) and clinical (grade, histology, tumor size, lymph node involvement, ER, PR, and HER-2 status) factors between women with secondary versus primary BC by age group at BC diagnosis (15–39, 40–64, and ≥ 65 years). Results are presented as odds ratio (OR) and corresponding 95% confidence intervals (CI). Multivariable Cox proportional hazards regression models were used to evaluate
associations of secondary versus primary BC, controlling for demographic and clinical factors, on breast cancer-specific survival (BCSS) by age group at BC diagnosis (15–39 years, 40–64 years, and ≥ 65 years). In addition, multivariable Cox proportional hazards regression models assessed the associations of secondary versus primary BC on BCSS by age group in subgroups defined by race/ethnicity and tumor receptor status. Effect modification was assessed between breast cancer (secondary vs primary) and each subgroup (age group and, within age group, by race/ethnicity and tumor receptors) by including interaction terms in the multivariable models. For deceased patients, survival time was measured from diagnosis date of the primary or secondary BC to the date of death from BC. Deaths from other causes were considered as competing risks. Patients alive at the study end date (31 December 2015) were censored at this date or at last known contact.

In all survival models, the proportional hazards assumption was assessed numerically based on cumulative sums of Martingale residuals and visually based on inspection of the survival curves [log (–log) of the survival distribution function by log (months)]; variables that violated this assumption were included as stratifying variables to allow for differing baseline hazards associated with these variables (chemotherapy, radiation, surgery, regional lymph nodes examined). Results are presented as hazard ratios (HR) and 95% confidence intervals (CI). Statistical analyses were performed using SAS statistical software (version 9.4), and a 2-sided P value of less than 0.05 was considered statistically significant.

RESULTS

A total of 37,625 females were diagnosed with an invasive BC as a secondary malignancy from 1991 to 2015 in the CCR. Of the cohort of secondary BC patients, most were of older age (15–39 years, n = 777; 40–64 years, n = 15,848; ≥ 65 years, n = 21,000). This was different from the age distribution for women diagnosed with primary BC (n = 377,167), where women aged 40–64 years comprised the largest proportion of patients (n = 205,101 vs 15–39 years, n = 23,298 and ≥ 65 years, n = 148,768) (Table 1).
| Characteristics                  | 15–39 years at diagnosis | 40–64 years at diagnosis | ≥ 65 years at diagnosis |
|---------------------------------|--------------------------|--------------------------|-------------------------|
|                                 | Only primary N = 23,298  | Secondary N = 777        | Only primary N = 205,101 | Secondary N = 15,848  |
|                                 | N (%)                    | N (%)                    | N (%)                   | N (%)                   |
| Race/ethnicity                  |                          |                          |                         |                         |
| Non-Hispanic White              | 10,809 (46.4)            | 368 (47.4)               | 125,351 (61.1)         | 10,084 (63.6)            |
| Non-Hispanic Black              | 1939 (8.3)               | 79 (10.2)                | 13,663 (6.7)           | 1284 (8.1)               |
| Hispanic                        | 6689 (28.7)              | 227 (29.2)               | 37,599 (18.3)          | 2599 (16.4)              |
| Asian/Pacific Islander          | 3581 (15.4)              | 101 (13.0)               | 25,830 (12.6)          | 1813 (11.4)              |
| Other/Unknown                   | 280 (1.2)                | <5 (0.3)                 | 2658 (1.3)             | 68 (0.4)                 |
| Year of diagnosis               |                          |                          |                         |                         |
| 1991–1995                       | 4362 (18.7)              | 75 (9.7)                 | 28,016 (13.7)          | 633 (4.0)                |
| 1996–2000                       | 4412 (18.9)              | 174 (22.4)               | 35,447 (17.3)          | 2052 (12.9)              |
| 2001–2005                       | 4603 (19.8)              | 197 (25.4)               | 42,456 (20.7)          | 3424 (21.6)              |
| 2006–2010                       | 4681 (20.1)              | 167 (21.5)               | 47,559 (23.2)          | 4532 (28.6)              |
| 2011–2015                       | 5240 (22.5)              | 164 (21.1)               | 51,623 (25.2)          | 5207 (32.9)              |
| Neighborhood SES                |                          |                          |                         |                         |
| Low SES                         | 12,550 (53.9)            | 421 (54.2)               | 100,373 (48.9)         | 7546 (47.6)              |
| High SES                        | 10,748 (46.1)            | 356 (45.8)               | 104,728 (51.1)         | 8302 (52.4)              |
| AJCC Stage                      |                          |                          |                         |                         |
| Stage I                         | 5843 (25.1)              | 279 (35.9)               | 86,774 (42.3)          | 8059 (50.9)              |
| Stage II                        | 11,186 (48.0)            | 264 (34.0)               | 77,877 (38.0)          | 4707 (29.7)              |
| Stage III                       | 3605 (15.5)              | 104 (13.4)               | 21,184 (10.3)          | 1382 (8.7)               |
| Stage IV                        | 1291 (5.5)               | 66 (8.5)                 | 9355 (4.6)             | 815 (5.1)                |
| Unknown                         | 1373 (5.9)               | 64 (8.2)                 | 9911 (4.8)             | 885 (5.6)                |
| Chemotherapy                    |                          |                          |                         |                         |
| Yes                             | 17,183 (73.8)            | 454 (58.4)               | 102,042 (49.8)         | 6505 (41.0)              |
| No/Unknown                      | 6115 (26.2)              | 323 (41.6)               | 103,059 (50.2)         | 9343 (59.0)              |
| Radiation                       |                          |                          |                         |                         |
| Yes                             | 10,213 (43.8)            | 233 (30.0)               | 98,386 (48.0)          | 5216 (32.9)              |
| No/unknown                      | 13,085 (56.2)            | 544 (70.0)               | 106,715 (52.0)         | 10,632 (67.1)            |
| Surgery                         |                          |                          |                         |                         |
| Lumpectomy                      | 8538 (36.6)              | 230 (29.6)               | 105,056 (51.2)         | 6129 (38.7)              |
| Mastectomy                      | 12,786 (54.9)            | 456 (58.7)               | 85,862 (41.9)          | 8286 (52.3)              |
| None                            | 1810 (7.8)               | 85 (10.9)                | 12,936 (6.3)           | 1318 (8.3)               |
| Unknown                         | 164 (0.7)                | 6 (0.8)                  | 1247 (0.6)             | 115 (0.7)                |
| Tumor grade                     |                          |                          |                         |                         |
| Grade I                         | 1578 (6.8)               | 55 (7.1)                 | 37,070 (18.1)          | 3004 (19.0)              |
| Grade II                        | 6829 (29.3)              | 223 (28.7)               | 76,486 (37.3)          | 6033 (38.1)              |
| Grade III                       | 11,965 (51.4)            | 386 (49.7)               | 68,162 (33.2)          | 5069 (32.0)              |
| Undifferentiated                | 668 (2.9)                | 23 (3.0)                 | 3445 (1.7)             | 242 (1.5)                |
| Unknown                         | 2258 (9.7)               | 90 (11.6)                | 19,938 (9.7)           | 1500 (9.5)               |
| Histology                       |                          |                          |                         |                         |
| Ductal                          | 18,834 (80.8)            | 588 (75.7)               | 153,595 (74.9)         | 11,400 (71.9)            |
| Lobular                         | 2182 (9.4)               | 96 (12.4)                | 34,692 (16.9)          | 3048 (19.2)              |
| Other                           | 2282 (9.8)               | 93 (12.0)                | 16,814 (8.2)           | 1400 (8.8)               |
| Tumor size                      |                          |                          |                         |                         |
| T1a: ≤ 0.5 cm                   | 878 (3.8)                | 68 (8.8)                 | 14,215 (6.9)           | 1725 (10.9)              |
| T1b: > 0.5–1 cm                 | 1631 (7.0)               | 92 (11.8)                | 29,892 (14.6)          | 2973 (18.8)              |
In the secondary BC cohort, women ≥ 65 years were less likely to be non-Hispanic (NH) Black (5.7% vs 15–39 years, 10.2% and 40–64 years, 8.1%), Hispanic (9.3% vs 15–39 years, 29.2% and 40–64 years, 16.4%), or Asian/Pacific Islander (6.7% vs 15–39 years, 13.0% and 40–64 years, 11.4%) race/ethnicity than younger women. Across all ages, women with secondary BC had smaller (T3: 15–39 years, 8.9% vs11.7%; 40–64 years, 5.3% vs 7.1%; ≥ 65 years, 4.3% vs 5.6%) and more lymph node negative (15–39 years, 37.8% vs 49.3%; 40–64 years, 28.1% vs 36.9%; ≥ 65 years, 20.7% vs 25.3%) tumors than their primary BC counterparts. Additionally, the percentage of secondary BC tumors that were ER and PR positive and HER-2 negative increased with age. However, regardless of age, secondary BC patients were more likely to be treated with mastectomy and less likely to receive chemotherapy or radiation.

In the multivariable logistic regression models, secondary BCs were more likely to occur among non-Hispanic Black AYAs (OR: 1.25; CI 0.97–1.61; borderline statistical significance) and middle-aged women (OR: 1.14; CI 1.07–1.21), but less likely to occur among middle-aged (OR: 0.80; CI 0.76–0.84) and older (OR: 0.72; CI 0.68–0.75) Hispanics and Asian/Pacific Islanders compared with non-Hispanic Whites in each age group (Table 2). Secondary BCs were more likely to be of higher grade at all ages, but this association did not reach statistical significance for women aged 15–39 years at diagnosis. In all age groups, secondary BCs were more likely to have lobular histology, be smaller in size, be lymph node negative and be ER/PR negative than primary BCs. HER-2 status was similar for women with primary and secondary BC by age.

### TABLE 1 continued

| Characteristics | 15–39 years at diagnosis | 40–64 years at diagnosis | ≥ 65 years at diagnosis |
|-----------------|--------------------------|--------------------------|-------------------------|
|                 | Only primary N = 23,298 N (%) | Secondary N = 777 N (%) | Only primary N = 205,101 N (%) | Secondary N = 15,848 N (%) | Only primary N = 148,768 N (%) | Secondary N = 21,000 N (%) |
| T1c: 1–2 cm     | 6486 (27.8) 241 (31.0) | 69,174 (33.7) 5232 (33.0) | 50,791 (34.1) 7357 (35.0) |
| T2: 2–5 cm      | 9638 (41.4) 210 (27.0) | 63,719 (31.1) 3804 (24.0) | 40,722 (27.4) 4985 (23.7) |
| T3: 5 cm        | 2737 (11.7) 69 ( 8.9) | 14,461 ( 7.1) 835 ( 5.3) | 8387 ( 5.6) 909 ( 4.3) |
| Diffuse         | 469 ( 2.0) 16 ( 2.1) | 2651 ( 1.3) 202 ( 1.2) | 1377 ( 0.9) 136 ( 0.6) |
| Other           | 1459 ( 6.3) 81 (10.4) | 10,989 ( 5.4) 1077 ( 6.8) | 11,641 ( 7.8) 1241 ( 5.9) |

**Lymph node involvement**

- **Positive:** 11,491 (49.3) 294 (37.8) 75,584 (36.9) 4451 (28.1) 37,595 (25.3) 4343 (20.7)
- **Negative:** 10,844 (46.5) 416 (53.5) 122,525 (59.7) 10,715 (67.6) 98,857 (66.5) 15,621 (74.4)
- **Unknown:** 963 ( 4.1) 67 ( 8.6) 6992 ( 3.4) 682 ( 4.3) 1377 ( 0.9) 136 ( 0.6)

**Lymph nodes examined**

- **Sentinel lymph node biopsy:** 6449 (27.7) 215 (27.7) 78,398 (38.2) 770 (42.7) 51,236 (34.4) 9009 (42.9)
- **Axillary lymph node dissection:** 14,299 (61.4) 375 (48.3) 106,850 (52.1) 6071 (38.3) 63,543 (42.7) 6559 (31.2)
- **No nodes examined/unknown:** 2550 (10.9) 187 (24.1) 19,853 ( 9.7) 3007 (19.0) 15,621 (74.4) 1036 ( 4.9)

**Estrogen receptor status**

- **Positive:** 12,989 (55.8) 366 (47.1) 140,906 (68.7) 10,720 (67.6) 103,416 (69.5) 15,772 (75.1)
- **Negative:** 7215 (31.0) 279 (35.9) 40,267 (19.6) 3361 (21.2) 18,848 (12.7) 2820 (13.4)
- **Unknown:** 3094 (13.3) 132 (17.0) 23,928 (11.7) 1767 (11.1) 26,504 (17.8) 2408 (11.5)

**Progesterone receptor status**

- **Positive:** 11,454 (49.2) 330 (42.5) 119,812 (58.4) 8592 (54.2) 84,423 (56.7) 12,675 (60.4)
- **Negative:** 8482 (36.4) 304 (39.1) 57,441 (28.0) 5196 (32.8) 34,987 (23.5) 5565 (26.5)
- **Unknown:** 3362 (14.4) 143 (18.4) 27,848 (13.6) 2060 (13.0) 29,358 (19.7) 2760 (13.1)

**HER-2 status**

- **Positive:** 3366 (26.5) 104 (23.2) 24,523 (19.6) 2069 (17.4) 10,983 (13.5) 2014 (12.6)
- **Negative:** 8222 (64.7) 277 (61.7) 87,563 (70.1) 8402 (70.5) 59,081 (72.6) 11,904 (74.7)
- **Unknown:** 1113 ( 8.8) 68 (15.1) 12,829 (10.3) 1454 (12.2) 11,326 (13.9) 2022 (12.7)

SES = Socioeconomic status; AJCC = American Joint Committee on Cancer; HER-2 = Human epidermal growth factor receptor-2

*HER-2 data is limited to 2003+ diagnoses
In multivariable survival models evaluating the impact of secondary versus primary BC, we found that the hazard of breast cancer death was higher for women with secondary BCs in all age groups, but the impact on survival diminished with age (15-39 years old, HR: 2.09, CI 1.83–2.39; 40–64 years old, HR: 1.51; 1.44–1.58, ≥ 65 years old, HR: 1.14; CI 1.10–1.19) (p for interaction < 0.001) (Fig. 2). Within age groups, the negative impact of secondary (vs primary) BC on BCSS persisted in all racial/ethnic groups, except Asian/Pacific Islanders ≥ 65 years (Fig. 3). While the negative impact of secondary BC did not differ significantly by race/ethnicity in AYAs (p = 0.30) or women ≥ 65 years (p = 0.59), the survival difference of a secondary BC compared with primary BC appeared to be greatest among non-Hispanic Black AYAs and least among Asian/Pacific Islanders ≥ 65 years. Racial/ethnic differences in survival were observed in middle-aged women (p = 0.03), with the negative impact of secondary BC more pronounced for Hispanics and Asian/Pacific Islanders than non-Hispanic Blacks.

In a subset of women diagnosed after 2003, we found that BCSS differences between secondary and primary BC based on tumor receptor status were evident in women 40–64 years and ≥ 65 years old (p < 0.001) (with borderline differences observed in AYAs based on tumor receptor status; p = 0.07) (Fig. 4). The impact of BCSS for

| TABLE 2 | Adjusted logistic regression model of factors associated with having secondary breast cancer compared with primary breast cancer |
|---------|---------------------------------------------------------------------------------------------------------------------------------|
|         | Characteristics                                                                 | OR (95% CI)  | OR (95% CI)  | OR (95% CI)  |
|         | 15–39 years at diagnosis                                      | 40–64 years at diagnosis                                      | ≥ 65 years at diagnosis                                      |
| Race/ethnicity | Non-Hispanic White Reference                                        | Reference       | Reference       | Reference       |
|         | Non-Hispanic Black                                             | 1.25 (0.97,1.61) | 1.14 (1.07,1.21) | 1.01 (0.95,1.08) |
|         | Hispanic                                                         | 1.02 (0.86,1.21) | 0.80 (0.76,0.84) | 0.72 (0.68,0.75) |
|         | Asian/Pacific Islander                                         | 0.80 (0.64,1.01) | 0.80 (0.76,0.84) | 0.73 (0.69,0.77) |
| Tumor grade | Grade I Reference                                               | Reference       | Reference       | Reference       |
|         | Grade II                                                        | 1.17 (0.86,1.60) | 1.14 (1.09,1.20) | 1.08 (1.04,1.12) |
|         | Grade III                                                       | 1.25 (0.92,1.71) | 1.18 (1.12,1.25) | 1.06 (1.01,1.11) |
|         | Undifferentiated                                                | 1.18 (0.71,1.97) | 1.13 (0.98,1.30) | 1.16 (1.00,1.35) |
| Histology | Ductal Reference                                                | Reference       | Reference       | Reference       |
|         | Lobular                                                         | 1.53 (1.22,1.92) | 1.24 (1.19,1.30) | 1.20 (1.16,1.25) |
| Tumor size | T1a: ≤ 0.5 cm Reference                                         | Reference       | Reference       | Reference       |
|         | T1b: > 0.5–1 cm                                                 | 0.80 (0.58,1.12) | 0.90 (0.84,0.96) | 0.82 (0.77,0.87) |
|         | T1c: > 1–2 cm                                                   | 0.52 (0.39,0.69) | 0.69 (0.65,0.73) | 0.72 (0.68,0.76) |
|         | T2: > 2–5 cm                                                    | 0.29 (0.22,0.39) | 0.55 (0.51,0.58) | 0.62 (0.58,0.66) |
|         | T3: > 5 cm                                                      | 0.33 (0.23,0.47) | 0.52 (0.48,0.57) | 0.54 (0.50,0.60) |
|         | Diffuse                                                         | 0.37 (0.20,0.66) | 0.81 (0.69,0.95) | 0.78 (0.64,0.94) |
| Lymph node involvement | Negative Reference                                             | Reference       | Reference       | Reference       |
|         | Positive                                                        | 0.80 (0.68,0.94) | 0.77 (0.74,0.80) | 0.82 (0.79,0.85) |
| ER and PR status | Positive Reference                                             | Reference       | Reference       | Reference       |
|         | Negative                                                        | 1.39 (1.17,1.67) | 1.26 (1.21,1.32) | 1.11 (1.06,1.17) |
| HER-2 status | Positive Reference                                              | Reference       | Reference       | Reference       |
|         | Negative                                                        | 1.09 (0.87,1.38) | 1.12 (1.06,1.18) | 1.03 (0.97,1.08) |

The estimates of odds ratios for unknown groups are not present.

OR = Odds ratio; CI = Confidence interval; ER = Estrogen receptor; PR = Progesterone receptor; HER-2 = Human epidermal growth factor receptor-2.

*Models adjusted for all variables in the Table as well as year of diagnosis and socioeconomic status.

bHER-2 data is limited to 2003+ diagnoses.
secondary compared with primary BC was most pronounced amongst women with hormone receptor positive, HER-2 negative disease across all ages. For women with HER-2 positive tumors, regardless of hormone receptor status, BCSS was only worse for secondary BCs amongst women 40–64 years old. BCSS was also significantly decreased in triple negative secondary BCs at all ages, but to a lesser extent.

**DISCUSSION**

In this large, population-based study, we found that BCSS was worse for women with secondary than primary BCs, and this difference was largest in the 15–39 age group, consistent with prior work.\(^2,4,7\) We additionally identified that the impact of secondary BC on survival differs by race/ethnicity and tumor subtype. Among 40- to 64-year-old women, the negative impact of secondary BC on BCSS was more pronounced among Hispanics and Asian/Pacific Islanders than non-Hispanic Blacks. However, this survival difference between secondary and primary BC was no longer seen in Asian/Pacific Islanders \(\geq 65\) years. Additionally, the negative impact of secondary BC was particularly substantial in women with hormone receptor positive BCs. This is the first study, to our knowledge, that examines secondary BC characteristics and outcomes compared with primary BCs across the age spectrum.

Little is known about survival in older patients with secondary BC, which is surprising as the majority of cancer survivors are 65 years of age or older.\(^8\) In primary BC, the best survival rates have been found for middle-aged women, with decreased survival at each end of the age spectrum.\(^15-17\) Confirming prior findings, we identified that AYA women with secondary BC experienced significantly worse BCSS than AYAs with primary BC.\(^6,7\) This may be
due to the inherent aggressive nature of these tumors, which can arise in radiated tissue after mantle or chest radiation, and may be genetically less treatment-responsive, such as triple negative tumors which are more likely found in AYA BRCA mutation carriers. Additionally, we found the most minimal BCSS difference between secondary and primary BCs in older women, perhaps because they tend to develop small, low-grade, hormone receptor positive tumors in both the primary and secondary cancer settings. It is well known that these types of BCs have relatively good prognosis in the primary BC setting, and our findings suggest that they have a similar prognosis in the secondary BC setting in older women as well.

Many studies have demonstrated differences in BC incidence rates and survival by race/ethnicity, but few studies have considered the impact of secondary BC (vs primary BC) by race/ethnicity and age. In our study, non-Hispanic Black women are more likely to have a second BC at all ages, but the difference in BCSS between secondary and primary BCs is less in middle-aged non-Hispanic Blacks than in all other racial/ethnic groups. This is most likely due to non-Hispanic Black women having poorer survival after primary BC compared with women of other race/ethnicities, thus making the difference in BCSS between the primary and secondary BCs less impactful. In contrast, Asian/Pacific Islanders and Hispanics have been found to have better primary BC prognosis than non-Hispanic Whites, which may have contributed to the significantly more pronounced detrimental impact of secondary BC on survival in middle-aged Asian/Pacific Islander and Hispanic women observed in our study. In women over 65 years, there was no difference in survival for Asian/Pacific Islanders between primary vs secondary BC. Our data show that there is something innately different about secondary BCs that modifies the differences seen traditionally by race/ethnicity, especially for middle-aged women who traditionally have the best survival. This may be related to types of cancer-predisposing treatment received previously (e.g., radiation) and genetic risk factors that are more common in certain racial and ethnic groups predisposing to specific types of malignancies. Additionally, the decreased BCSS may be related to prior treatment regimens received for their primary cancer impacting their further use for secondary BC treatment, such as mantle radiation being used to treat lymphoma, thus eliminating it from the armamentarium available for a patient’s secondary BC treatment.

Breast cancer is a complex and heterogeneous disease for which therapeutic molecular markers are known to affect BCSS. In primary BC, hormone (estrogen/progesterone) receptor positive BC has been shown to have the best BCSS, and many women with these tumor types get de-escalated care at older ages for this subtype of disease. Not much is known about molecular markers and survival in secondary BC. In middle-aged and older women, the impact of secondary BC on BCSS was most pronounced among women who have hormone receptor positive disease (ER/PR positive, HER-2 negative), the most common
tumor subtype in this age group.\(^7,29\) We also observed that middle-aged women with HER-2 positive or triple negative tumors had fewer differences in BCSS between primary and secondary BC than hormone receptor positive disease, which might stem from the already decreased BCSS seen in these subtypes in primary BC compared with hormone receptor positive BCs.

Our database has limitations in that we lacked full treatment details. The radiation fields are not specified, and chemotherapeutic agents are unknown. In addition, there are no genetic data collected, which can influence treatment decisions and risk for secondary BC, especially for patients who have a BRCA mutation. Additionally, due to the nature of the database, there is no information about treatment failure (e.g., locoregional or distant recurrences). Lastly, the smaller secondary BC cohort in AYAs (2% of secondary BC in our study) could have impacted our ability to identify differences in patient subgroups and should be the focus of future research. Despite these limitations, the current study represents over 99% of all cancers diagnosed in California and includes a racially and ethnically diverse set of patients from a population-based registry, increasing the generalizability of our results.

In conclusion, we found that BCSS is significantly decreased among all women that develop a secondary BC compared with those with a primary BC; however, BCSS differences between secondary and primary BC are greatest for women who have hormone receptor positive disease or are of Hispanic and Asian/Pacific Islander ethnicity: groups of women who often have superior survival after primary BC. Additional research is needed to help translate these findings into improved individualized treatments and screenings for secondary BC amongst women with poor prognosis.

ACKNOWLEDGMENTS Thank you to the University of California, Davis for the institutional funding to support this project. Thank you to Dr. Frederick Meyers for support and guidance on this topic.

AUTHORS’ CONTRIBUTIONS Concept and design: CAMS, THMK. Acquisition and analysis of data: QL Drafting of the manuscript: CAMS, THMK. Review, editing and final approval: CAMS, QL, Bold, KJR, THMK

FUNDING Institutional support was received from the University of California, Davis and UC Davis Comprehensive Cancer Center Support Grant (P30CA093373-16). The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention’s National Program of Cancer Registries, under cooperative agreement 5NU58DP006344; the National Cancer Institute’s SEER Program under contract HHSN261201800032I awarded to the University of California, San Francisco, contract HHSN261201800015I awarded to the University of Southern California, and contract HHSN261201800091 awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the opinions of the State of California, Department of Public Health, National Cancer Institute, and Centers for Disease Control and Prevention or their contractors and subcontractors.

DISCLOSURE The authors declare no potential conflicts of interest.

OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

REFERENCES

1. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85.
2. Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomark Prev. 2006;15(11):2020–6.
3. Lee JS, DuBois SG, Coccia PF, Bleyer A, Olin RL, Goldsby RE. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer. 2016;122(1):116–23.
4. Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. New Engl J Med. 2015;373(26):2499–511.
5. Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 2017;3(11):1554–7.
6. Sadler C, Goldfarb M. Comparison of primary and secondary breast cancers in adolescents and young adults. Cancer. 2015;121(8):1295–302.
7. Sauder CAM, Li Q, Othieno A, et al. Characteristics and outcomes for secondary breast cancer in childhood, adolescent, and young adult cancer survivors treated with radiation. Cancer Epidemiol Biomark Prev. 2020;29(9):1767–74.
8. Valdivieso M, Kujawa AM, Jones T, Baker LH. Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci. 2012;9(2):163–73.
9. Hiatt RA, Tai CG, Blayney DW, et al. Leveraging state cancer registries to measure and improve the quality of cancer care: a potential strategy for California and beyond. J Natl Cancer Inst. 2015;107(5).
10. Goldfarb M, Rosenberg AS, Li Q, Keegan THM. Impact of latency time on survival for adolescents and young adults with a second primary malignancy. Cancer. 2018;124(6):1260–8.
11. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109(9):1721–8.
12. Keegan THM, Press DJ, Tao L, et al. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res. 2013;15(5):R95.
13. Keegan TH, DeRouen MC, Parsons HM, et al. Impact of treatment and insurance on socioeconomic disparities in survival after adolescent and young adult Hodgkin lymphoma: a population-based study. Cancer Epidemiol Biomark Prev. 2016;25(2):264–73.
14. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;12(8):703–11.
15. Brandt J, Garne JP, Tengrup I, Manjer J. Age at diagnosis in relation to survival following breast cancer; a cohort study. World J Surg Oncol. 2015;13(1):33.
16. El Saghir NS, Seoul M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer. 2006;6:194.
17. Holli K, Isola J. Effect of age on the survival of breast cancer patients. Eur J Cancer. 1997;33(3):425–8.
18. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.
19. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.
20. Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER cancer statistics review, 1975–2015. https://seer.cancer.gov/csr/1975_2015/. Accessed April 2018.
21. Boyer-Chammard A, Taylor TH, Anton-Culver H. Survival differences in breast cancer among racial/ethnic groups: a population-based study. Cancer Detect Prev. 1999;23(6):463–73.
22. Curtis E, Quale C, Haggstrom D, Smith-Bindman R. Racial and ethnic differences in breast cancer survival: How much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer. 2008;112(1):171–80.
23. Albaik KS, Unger JM, Crowley JJ, Colman CA Jr, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst. 2009;101(14):984–92.
24. Maskarinec G, Sen C, Koga K, Conroy SM. Ethnic differences in breast cancer survival: status and determinants. Women’s Health (Lond). 2011;7(6):677–87.
25. McCracken M, Olsen M, Chen MS Jr, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese Ethnicities. CA Cancer J Clin. 2007;57(4):190–205.
26. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165–73.
27. Miller KD, Goding Sauer A, Ortiz AP, et al. Cancer statistics for Hispanics/Latinos. CA Cancer J Clin. 2018;68(6):425–45.
28. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971–7.
29. Brown M, Bauer K, Pare M. Tumor marker phenotype concordance in second primary breast cancer, California, 1999–2004. Breast Cancer Res Treat. 2010;120(1):217–27.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.